𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Body mass index and clinical response to infliximab in rheumatoid arthritis

✍ Scribed by Ruth Klaasen; Carla A. Wijbrandts; Danielle M. Gerlag; Paul P. Tak


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
93 KB
Volume
63
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Prognostic importance of low body mass i
✍ Hilal Maradit Kremers; Paulo J. Nicola; Cynthia S. Crowson; Karla V. Ballman; Sh πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## Abstract ## Objective Various etiologic mechanisms have been implicated in the observed increase in cardiovascular mortality in rheumatoid arthritis (RA). Body mass index (BMI) is associated with cardiovascular mortality in the general population. This study compared the effect of BMI on cardio

Radiographic joint damage in early rheum
✍ Gisela Westhoff; Rolf Rau; Angela Zink πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 1 views

## Abstract ## Objective To investigate the association between body mass index (BMI) and radiographic joint damage (using the Ratingen Score [RS]) in early rheumatoid arthritis (RA). ## Methods The study was carried out in 767 patients with early RA. Standard clinical data, RS, and BMI were eva

Association of the major histocompatibil
✍ Alfonso Martinez; Marina Salido; Gema Bonilla; Dora Pascual-Salcedo; Miguel Fern πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 67 KB πŸ‘ 2 views

## Objective: To determine whether major histocompatibility complex (mhc) polymorphisms are associated with a good or poor response to infliximab therapy in patients with rheumatoid arthritis (ra). ## Methods: Seventy-eight infliximab-treated patients with ra were genotyped for hla-drb1, hla-dqa1

Development of antiinfliximab antibodies
✍ Gerrit Jan Wolbink; Marijn Vis; Willem Lems; Alexandre E. Voskuyl; Els De Groot; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 80 KB πŸ‘ 2 views

## Abstract ## Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, may result in the formation of infliximab‐specific IgG antibodies. This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthr